Tumor necrosis factor alpha-induced protein 3: A key biomarker for response to ursodeoxycholic acid in primary biliary cholangitis
Authors:
- Bo ZangBZBo Zang
- Jia-Xiu LiJLJia-Xiu Li
- Qi-Xuan LiuQLQi-Xuan Liu
- Yuan YaoYYYuan Yao
- Hua LiHLHua Li
- Yan WangYWYan Wang
- Ji-Gang WangJWJi-Gang Wang
- Yi-Fei YangYYYi-Fei Yang
- Rui-Wen LiangRLRui-Wen Liang
- Xin-Ran XinXXXin-Ran Xin
- Bin LiuBLBin Liu
Open Access
- 27 July 2025
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 17 (7)
Abstract
BACKGROUND The pathogenesis of primary biliary cholangitis (PBC) remains unclear. Ursodeoxycholic acid (UDCA) is the only first-line clinical treatment, but approximately 40% of patients exhibit a poor response. AIM To identify novel biomarkers for PBC to predict the efficacy of UDCA and enhance treatment. METHODS Microarray expression profiling datasets were downloaded from the Gene Expression Omnibus and analyzed to identify differentially expressed genes between PBC patients and healthy controls. Immunohistochemistry was performed to validate key genes in liver tissues of the participants. Logistic regression was employed to evaluate prognostic risk factors, receiver operating characteristic curves were used to assess predictive performance, and correlations between key genes and clinicopathological characteristics were analyzed. RESULTS By bioinformatic analysis, 13 genes primarily associated with the progression of PBC were identified, and tumor necrosis factor alpha-induced protein 3 (TNFAIP3) was selected for further investigation. Then expression of TNFAIP3 in PBC patients was significantly elevated compared to healthy controls on immunohistochemistry (P < 0.0001). Multivariate Cox regression analysis indicated that both TNFAIP3 and fatigue were independent risk factors for response to UDCA in PBC patients (P < 0.05). The area under the curve for TNFAIP3 and fatigue were 0.691 and 0.704, respectively, while their combination showed a significantly higher area under the curve of 0.848. The expression of TNFAIP3 was also correlated with age, albumin, total bilirubin, alkaline phosphatase and splenomegaly (P < 0.05). CONCLUSION TNFAIP3 and fatigue are independent risk factors for response to UDCA in Chinese patients with PBC. TNFAIP3 may be a potential biomarker or therapeutic target for PBC. These findings offer new insights into the pathogenesis of PBC.Keywords
This publication has 37 references indexed in Scilit:
- Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcomeJournal of Hepatology, 2011
- A failure of TNFAIP3 negative regulation maintains sustained NF-κB activation in Sjögren’s syndromeHistochemistry and Cell Biology, 2011
- Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary CirrhosisAmerican Journal of Gastroenterology, 2010
- Primary biliary cirrhosisSeminars in Immunopathology, 2009
- Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibilityArthritis Research & Therapy, 2009
- Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assayHepatology, 2008
- Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosusNature Genetics, 2008
- Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosisHepatology, 2008
- Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic AcidGastroenterology, 2006
- Failure to Regulate TNF-Induced NF-κB and Cell Death Responses in A20-Deficient MiceScience, 2000